Affimed - AFMD Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year target prices for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $6.71 in the next twelve months. This suggests a possible upside of 461.9% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.

Affimed's stock was trading at $1.24 at the beginning of the year. Since then, AFMD stock has decreased by 3.6% and is now trading at $1.1950.
View the best growth stocks for 2023 here.

Affimed saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 3,410,000 shares, a decline of 15.0% from the December 31st total of 4,010,000 shares. Based on an average daily trading volume, of 2,130,000 shares, the short-interest ratio is currently 1.6 days.
View Affimed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our AFMD earnings forecast.

Affimed (NASDAQ:AFMD) announced its quarterly earnings data on Tuesday, November, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.08. The biopharmaceutical company had revenue of $15.01 million for the quarter, compared to analyst estimates of $7.66 million. Affimed had a negative trailing twelve-month return on equity of 48.46% and a negative net margin of 189.04%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Affimed's stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.73%), Intellectus Partners LLC (0.30%), Knights of Columbus Asset Advisors LLC (0.19%), Harbor Investment Advisory LLC (0.06%), Diversified Trust Co (0.04%) and SG Americas Securities LLC (0.02%).

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFMD stock can currently be purchased for approximately $1.20.

Affimed (NASDAQ:AFMD) has a market capitalization of $147.49 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

The company employs 197 workers across the globe.

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.